Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Reports

New York (PRWEB) September 11, 2014

Byetta lawsuits ( and legal claims involving other incretin mimetic Type 2 diabetes drugs, including Januvia and Victoza, continue to move forward in a federal multidistrict litigation now underway in U.S. District Court, Southern District of California, Bernstein Liebhard LLP reports. According to an Order issued on August 14, 2014, U.S. District Judge Anthony Battaglia has established guidelines and protocols governing the grounds upon which a party may assert the attorney client privilege or the work product doctrine, and withhold and/or redact information on those bases. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)

Our Firm continues to hear from individuals who were allegedly harmed by Byetta and other incretin mimetics. We are pleased that this proceeding is moving forward, says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Byetta lawsuit evaluations to patients who may have been harmed by this drug.

Byetta Lawsuit Allegations

Court records indicate that the litigation surrounding incretin mimetics has been growing since March 2013, when the U.S. Food & Drug Administration (FDA) announced it was investigating findings from an unpublished study that indicated their use could be associated with precancerous changes in the cells of the pancreas. Though the agency has been unable to conclude that such a link exists, its review is ongoing.

In April of that year, the Institute for Safe Medicine Practices revealed that the FDA had received 263 reports of pancreatitis, 71 cases of pancreatic cancer, and 14 incidents of thyroid cancer among patients taking Byetta in a single 12-month period. The same review also found that compared to other classes of diabetes medications, incretin mimetics were far more likely to be associated with pancreatic cancer.*

According to court documents, more than 480 lawsuits have been filed in the Southern District of California on behalf of individuals who allegedly developed pancreatitis due to their use of Byetta, Januvia or Victoza. All of the lawsuits allege that the drugs manufacturers failed to warn doctors and patients about their potentially harmful effects on the pancreas, as well as their alleged association with an increased risk of pancreatic cancer.

In addition to the claims pending in the federal proceeding, court documents show that a number of Byetta lawsuits involving similar allegations have been consolidated in a state-level litigation underway in California Superior Court. (In re: Byetta Cases, JCCP No. 4574)

Individuals who used Byetta or another incretin mimetic may be entitled to compensation if they develop pancreatitis, pancreatic cancer or thyroid cancer allegedly related to the medication. To learn more about filing a Byetta lawsuit, please visit Bernstein Liebhard LLPs website. For a free legal review, please call 800-511-5092.

*, ISMP, April 2013

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $ 3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016



This entry was posted in AI SEO and tagged , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply